Hubbard on assignment at FDA
This article was originally published in The Rose Sheet
Executive SummaryFormer FDA associate commissioner Bill Hubbard, an oft-quoted critic of the agency, leaves his advising position at the advocacy group Alliance for a Stronger FDA to return to FDA temporarily. In a May 27 e-mail, Hubbard said he is working in the Office of the Commissioner to help the new leadership in "getting things going." As for the regulatory areas or issues he is addressing, Hubbard said his duties are not limited
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.